“This raise is overwhelmingly backed by strategic investors across the oncology care delivery landscape, including payers, providers, employers, and health systems who deeply understand the complex needs of oncology populations and who see firsthand the impact of Thyme Care’s model,” said Thyme Care President and Chief Operating Officer Brad Diephuis, MD. “This is evidence that oncology can lead the way in building scalable models of shared accountability and impact that healthcare has long needed.”